Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

LESSONS LEARNED. RAS‐ or BRAF‐mutated metastatic colorectal cancers (mCRCs) progressing after first‐line treatment have a poor prognosis. European and U.S. guidelines include the multikinase inhibitor regorafenib as a standard option for second‐line therapy and beyond, based on the results of the ra...

Descripción completa

Detalles Bibliográficos
Autores principales: García‐Alfonso, Pilar, Benavides, Manuel, Falcó, Esther, Muñoz, Andrés, Gómez, Auxiliadora, Sastre, Javier, Rivera, Fernando, Montagut, Clara, Salgado, Mercedes, López‐Ladrón, Amelia, López, Rafael, Ruiz de Mena, Inmaculada, Durán, Gema, Aranda, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291325/
https://www.ncbi.nlm.nih.gov/pubmed/30120161
http://dx.doi.org/10.1634/theoncologist.2018-0316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291325/
https://www.ncbi.nlm.nih.gov/pubmed/30120161
http://dx.doi.org/10.1634/theoncologist.2018-0316

Ejemplares similares